In this edition of Psoriasis Prime Time, the faculty reviews the unique mechanism of action for allosteric tyrosine kinase 2 (TYK2) inhibitors compared with Janus kinase inhibitors, highlights the efficacy and safety data for the new TYK2 inhibitor in psoriasis, and uses a case-based discussion to illustrate how TYK2 inhibition can be incorporated into psoriasis treatment.
- Provider:Paradigm Medical Communications, LLC
- Activity Link: https://ce.paradigmmc.com/a/ZNKWWN
- Start Date: 2024-06-19 05:00:00
- End Date: 2024-06-19 05:00:00
- Credit Details: AMA PRA Category 1 Credit™️: 0.5 hours
- Commercial Support: Source: Bristol-Myers Squibb Company - Amount: 63233.75 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner Competence, Learner Knowledge, Learner Performance
- Provider Ship: Directly Provided
- Registration: Open to all
Subscribe
Login
0 Comments
Oldest